Nissar A. Darmani
Department of Pharmacology
Kirksville College of Osteopathic Medicine
MO 63501
USA
Name/email consistency: high
- Antiemetic and motor-depressive actions of CP55,940: cannabinoid CB1 receptor characterization, distribution, and G-protein activation. Darmani, N.A., Sim-Selley, L.J., Martin, B.R., Janoyan, J.J., Crim, J.L., Parekh, B., Breivogel, C.S. Eur. J. Pharmacol. (2003)
- Behaviorally active doses of the CB1 receptor antagonist SR 141716A increase brain serotonin and dopamine levels and turnover. Darmani, N.A., Janoyan, J.J., Kumar, N., Crim, J.L. Pharmacol. Biochem. Behav. (2003)
- The potent emetogenic effects of the endocannabinoid, 2-AG (2-arachidonoylglycerol) are blocked by delta(9)-tetrahydrocannabinol and other cannnabinoids. Darmani, N.A. J. Pharmacol. Exp. Ther. (2002)
- Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A. Darmani, N.A. Neuropsychopharmacology (2001)
- Cannabinoids of diverse structure inhibit two DOI-induced 5-HT(2A) receptor-mediated behaviors in mice. Darmani, N.A. Pharmacol. Biochem. Behav. (2001)
- Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB(1) receptors in the least shrew. Darmani, N.A. Pharmacol. Biochem. Behav. (2001)
- The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2. Darmani, N.A. Eur. J. Pharmacol. (2001)
- Early postnatal cocaine exposure causes sequential, dose-dependent, enduring but reversible supersensitivity in 5-HT2A receptor-mediated function during development in male mice. Darmani, N.A., Ahmad, B. Neurotoxicol. Teratol (2000)